DS Biopharma Limited
Records under this name other than the patents DS Biopharma Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,670,126 | Methods of making 15-hydroxy fatty acid derivatives Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,047,033 | Compositions Comprising Oxo-Derivatives of Fatty Acids and Methods of Making and Using Same Formerly held In force · High confidence | In force | High confidence | |
| US 12,017,986 | Compositions Comprising Oxo-Derivatives of Fatty Acids and Methods of Making and Using Same Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,570,083 | Compositions Comprising Oxo-Derivatives of Fatty Acids and Methods of Making and Using Same Formerly held In force · High confidence | In force | High confidence | |
| US 10,017,453 | Pharmaceutically Acceptable Salts of Fatty Acids Lapsed on the fee record Ended Jul 10, 2026 · High confidence | Lapsed on the fee record | Ended Jul 10, 2026 | High confidence |
| US 8,729,126 | Use of pufas for treating skin inflammation Lapsed on the fee record Ended May 20, 2026 · USPTO record | Lapsed on the fee record | Ended May 20, 2026 | USPTO record |
| US 9,889,106 | Topical compositions comprising polyunsaturated fatty acids Lapsed on the fee record Ended Feb 13, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 13, 2026 | USPTO record |
| US 9,855,236 | Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof Lapsed on the fee record Ended Jan 2, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 2, 2026 | USPTO record |
| US 8,536,223 | Use of PUFAs for treating skin inflammation Lapsed on the fee record Ended Sep 17, 2025 · USPTO record | Lapsed on the fee record | Ended Sep 17, 2025 | USPTO record |
| US 9,682,055 | Pharmaceutical compositions comprising DGLA and use of same Lapsed on the fee record Ended Jun 20, 2025 · USPTO record | Lapsed on the fee record | Ended Jun 20, 2025 | USPTO record |